The survival rate analysis of 130 patients with nonsmall-cell lung cancer who did not receive any specific anticancer therapy showed no statistically significant differences in the survival rates between various TNM combinations classified into stage groups II, lIla, ITlb, and IV, as proposed by Mountain in 1989 The most important factor in designing a meaningful staging system is to identify and give proportional weight to those factors that reliably and validly predict the survival of a patient. All studies regarding the survival of patients with lung cancer were done after they had received one or more therapeutic modalities. In this study, we describe the survival rate analysis of patients with non-small-cell lung cancer who did not receive any type of therapeutic modality. These results add to the understanding of the real biologic behavior of lung tumors and/or host tumor relationship. stage group was composed of only the TI, 2N0, MO combination, and the second of all other TNM combinations. In a purely biologic sense of tumor growth, the lymph node involvement appeared to be the crucial factor determining the length of survival.
The survival rate analysis of 130 patients with nonsmall-cell lung cancer who did not receive any specific anticancer therapy showed no statistically significant differences in the survival rates between various TNM combinations classified into stage groups II, lIla, ITlb, and IV, as proposed by Mountain in 1989 and adopted by the American Joint Committee on Cancer. Following these findings, based on survival probabilities, two distinctive staging groups could be distinguished. The first Lung cancer is a major cause of cancer death throughout the world, in both developed and developing countries.' It is estimated that, at current incidence rates, there will be 590,000 new cases of lung cancer each year in the world. 2 The incidence of lung cancer is increasing rapidly in both sexes. 3 To ensure mutual understanding between researches, four decades ago Pierre Denoix proposed the TNM system for the classification of the anatomic extent of disease in patients with cancer. 4 In addition to its role as an accurate communication about the patient's status, the purpose of this staging is to aid in the selection of treatment, in the estimation of the probability of cure and survival, and in the comparison of the results from different clinical treatment studies.
The most important factor in designing a meaningful staging system is to identify and give proportional weight to those factors that reliably and validly predict the survival of a patient. All studies regarding the survival of patients with lung cancer were done after they had received one or more therapeutic modalities. In this study, we describe the survival rate analysis of patients with non-small-cell lung cancer who did not receive any type of therapeutic modality. These results add to the understanding of the real biologic behavior of lung tumors and/or host tumor relationship. The possible reason for that difference in ratios is that in our population, women are smoking less frequently and less number of cigarettes, and also that they were slightly more acceptable for the specific oncologic therapy. Although there are biologic differences between epidermoid carcinoma (61 cases, 46.9%), large-cell carcinoma (34 cases, 26.2%), and adenocarcinoma (35 cases, 26.9%), they were all combined in one survival study.
METHODS
Distribution of different types of non-small-cell carcinomas in this study were similar to these already published.' 7 Small-cell carcinoma cases were excluded because of the large difference between non-small-cell lung cancers and small-cell carcinoma of the lung.8 Table 1 . Because of the small number of patients with diagnosed lung cancer that constitute T1,NO,M0 group, and also that a small number of them were untreated, the Tl,NO,MO subset has not been included in this study. Figure 2 presents the survival relationship between the two newly created stage groups based on the analysis of 130 untreated patients with non-small-cell lung cancer as presented in Figure 1 . Namely, this analysis condensed T2,NO,MO subset into one stage and all other TNM subsets into the other stage. This simplification clearly disclosed the existence of statistically significant differences (p<0.001) in survival rates between those two stage groups. Medium survival rate for group 1 (Fig 1) was 17 months, while medium survival rate for group 2 patients was 8 months. 
